Want to track ABCL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABCL earnings report is expected in 64 days (6 May 2026)
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.
Fool | 1 year ago
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 1 year ago
Down 57%, Is AbCellera Biologics a Buy on the Dip?
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.
Fool | 1 year ago
